This site is intended for Healthcare professionals only.
×

Hikma Pharma guides for injectables growth after profit surge


Hikma Pharma guides for injectables growth after profit surge

The Jordan-based, Hikma Pharma said its core operating profit rose to $460 million for the year ended Dec. 31 from $386 million a year earlier.

New Delhi: Hikma Pharmaceuticals Plc on Wednesday reported a 19 per cent rise in full-year core operating profit, helped by strong demand for its injectable drugs and a rebound in its generics business.

The Jordan-based drugmaker said its core operating profit rose to $460 million for the year ended Dec. 31 from $386 million a year earlier.

Also Read: Hikma wins right to market Roche drug copy in Middle East and North Africa

Core revenue rose 7 per cent to $2.08 billion, with Hikma’s injectables business accounting for about 40 per cent of the total.

Hikma Pharmaceuticals is a multinational pharmaceutical company with headquarters in London, UK that manufactures non-branded generic and in-licensed pharmaceutical products.
It was founded in Amman, Jordan in 1978 by Samih Darwazah. It is listed on the London Stock Exchange and is a constituent of the FTSE 100 Index.

Spread the love


Source: With input
0 comment(s) on Hikma Pharma guides for injectables growth after profit surge

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted